Back to briefingOn watchUnited KingdomFinancial marketsAug 31, 2026, 8:56 PMProtagonist Therapeutics stock rating maintained at Buy by Clear StreetProtagonist Therapeutics stock rating maintained at Buy by Clear StreetRead original sourceToday's stories